Kong Dewei, Yu Haojie, Sim Xueling, White Kevin, Tai E Shyong, Wenk Markus, Teo Adrian Kee Keong
Stem Cells and Diabetes Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.
Dean's Office, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Front Digit Health. 2022 May 2;4:845405. doi: 10.3389/fdgth.2022.845405. eCollection 2022.
In the past one or two decades, countries across the world have successively implemented different precision medicine (PM) programs, and also cooperated to implement international PM programs. We are now in the era of PM. Singapore's National Precision Medicine (NPM) program, initiated in 2017, is now entering its second phase to generate a large genomic database for Asians. The National University of Singapore (NUS) also launched its own PM translational research program (TRP) in 2021, aimed at consolidating multidisciplinary expertise within the Yong Loo Lin School of Medicine to develop collaborative projects that can help to identify and validate novel therapeutic targets for the realization of PM. To achieve this, appropriate data collection, data processing, and results interpretation must be taken into consideration. There may be some difficulties during these processes, but with the improvement of relevant rules and the continuous development of omics-based technologies, we will be able to solve these problems, eventually achieving precise prediction, diagnosis, treatment, or even prevention of diseases.
在过去的一二十年里,世界各国相继实施了不同的精准医学(PM)项目,还合作实施了国际PM项目。我们现在正处于精准医学时代。新加坡于2017年启动的国家精准医学(NPM)项目,目前正进入第二阶段,旨在为亚洲人建立一个大型基因组数据库。新加坡国立大学(NUS)也于2021年启动了自己的精准医学转化研究项目(TRP),旨在整合杨秀桃医学院内的多学科专业知识,开展合作项目,以帮助识别和验证新的治疗靶点,从而实现精准医学。要做到这一点,必须考虑适当的数据收集、数据处理和结果解读。在这些过程中可能会遇到一些困难,但随着相关规则的完善和基于组学技术的不断发展,我们将能够解决这些问题,最终实现疾病的精准预测、诊断、治疗甚至预防。